MenopauseDigest — Connected Through ChangeEvidence Radar Active

Evidence Radar active · 48 validated items in archive

Validated
Evidence.
Real Understanding.

MenopauseDigest monitors, validates, and interprets the evidence shaping the menopause transition. Our Evidence Radar continuously scans clinical research, guidance, and reporting—so you can see what is established, what is emerging, and what remains uncertain.

MenopauseDigest is not a destination for answers. It is a place for understanding.

Why MenopauseDigest Exists

Between rigor and reach sits a widening Noise Gap.

For women navigating perimenopause and menopause, information arrives from every direction. Social media offers confidence and certainty, often without accountability. Medical research offers rigor and depth, but in language that assumes clinical training and time most people do not have.

MenopauseDigest was created in response to that failure. We exist to provide Intelligence for the Transition—not opinions, not prescriptions, and not products. We use technology and disciplined editorial standards to gather, interrogate, and translate menopause research so women can understand what is known, what is uncertain, and what questions are worth asking.

Read Our Story →

Trust Framework

Credibility before content.

Understanding requires trust, and trust requires standards. MenopauseDigest is deliberately separated from sponsored content, commercial influence, unverified claims, and algorithm-driven health feeds. These are the standards that make the rest of the platform meaningful.

Non-Commercial Feed

No sponsorships, no affiliate deals, no commercial influence shaping what we cover.

Pure Editorial

Independent editorial judgment. No paid placements, no advertorials, no hidden incentives.

Direct Sourcing

Every item links to its primary source so you can verify the evidence yourself.

Local Privacy

Search history, reflections, and translations stay on your device—never on our servers.

Evidence Classification Framework

Understanding the maturity of the evidence.

Classification is not about organizing content. It is about helping you judge how much weight any finding deserves. Every item is tagged by domain and by epistemic status so you can see, at a glance, how settled or how provisional the evidence really is.

Epistemic Status

Established / Validated

Findings supported by replication and consensus clinical guidance—evidence you can lean on with confidence.

Recent / Emerging

New studies and developing signals worth knowing about, but not yet settled. We flag them so you can weigh the uncertainty.

Domains

Medical

Clinical research, hormone therapy, symptoms, and treatment evidence.

Wellness

Lifestyle, nutrition, exercise, and behavioral interventions.

Relational

Partnership, family, and the relational dimensions of the transition.

Society

Workplace, policy, and cultural framing of midlife health.

Evidence Archive

Organized by evidence quality, not popularity.

The archive is not a feed and not a ranking. Each item is classified by the maturity of its evidence so you can see, at a glance, what deserves confidence and what deserves continued observation. The archive answers what is happening. The Editorial Series help answer what it means.

Established / Validated

Supported by replication, consensus guidance, or enduring research.

Recent / Emerging

Important and noteworthy, but still developing. Weigh with care.

Established / Validated

VerifiedMedical

Comment on: Older age and low testosterone levels are independently associated with kidney stone prevalence in men: results from a large cross-sectional study | International Journal of Impotence Research

This article is a commentary on a cross-sectional study by Kang et al. that found an association between older age, low testosterone levels, and kidney stone prevalence in men. The authors of this comment emphasize that due to the cross-sectional design, it is unclear whether low testosterone precedes stone formation or arises concurrently with conditions linked to nephrolithiasis. They suggest that shared metabolic factors might explain the observed association rather than low testosterone directly causing kidney stones.

Nature

Peer-Reviewed Journal

Last reviewed May 18, 2024

Recent / Emerging

VerifiedMedical

Menopause hormone therapy slashes risk of low bone density, new data shows

A new retrospective cohort study presented at ENDO 2026 suggests that menopausal hormone therapy (MHT) significantly reduces the risk of low bone mineral density and fractures in postmenopausal women. The study found that women using MHT had a 69% lower risk of low bone mineral density compared to those not on the treatment. This adds to existing evidence supporting MHT's bone protection benefits.

Medical News Today

Last reviewed Jun 14, 2026

Established / Validated

VerifiedMedical

Testosterone Information | FDA

The U.S. Food and Drug Administration (FDA) provides information on testosterone products, noting they are approved for men with diagnostically low testosterone levels due to associated medical conditions, not merely age-related decline. Following a review of the TRAVERSE trial and other data, the FDA updated prescribing information in June 2026, removing the limitation on age-related hypogonadism and revising safety information regarding prostate cancer.

U.S. Food and Drug Administration

Last reviewed Jun 23, 2026

Established / Validated

VerifiedMedical

Menopause and NIH Women's Health Research

This NIH page provides an overview of menopause, including its signs, symptoms, risk factors, diagnosis, and treatment approaches. It highlights ongoing research efforts funded by NIH, such as the SWAN study and work within the Intramural Research Program, focusing on improving understanding and management of menopausal health concerns.

discoverwhr.nih.gov

Government Health Org

Last reviewed Jun 12, 2026

Established / Validated

VerifiedMedical

Low Testosterone Levels and Grade Group Progression Among Localized Prostate Cancer Patients on Active Surveillance: A Retrospective Cohort Study - PubMed

This study investigated the link between baseline serum testosterone levels and the progression of localized prostate cancer in men undergoing active surveillance. It found that low testosterone (≤ 300 ng/dL) was significantly associated with an increased risk of progression to higher-grade prostate cancer (Grade Group 3 or higher). However, no clear association was found between low testosterone and moderate progression (Grade Group 2).

PubMed

Peer-Reviewed Journal

Last reviewed May 15, 2024

Recent / Emerging

VerifiedMedical

Clinical trials suggest GLP-1s may improve fertility in men with obesity

This press release from the Endocrine Society discusses research presented at ENDO 2026 showing that GLP-1s do not harm male hormones or fertility after long-term use. The study suggests GLP-1s may improve testosterone levels and sperm quality in men with obesity-related low testosterone, offering an alternative to testosterone replacement by addressing the underlying cause of excess weight and poor metabolic health.

www.endocrine.org

Last reviewed Jun 13, 2026

Recent / Emerging

VerifiedMedical

Real-World Study Backs Menopausal Hormone Therapy for Stronger Bones

A retrospective cohort study presented at ENDO 2026 found that menopausal hormone therapy (MHT) was associated with a significantly reduced risk of low bone mineral density (BMD) in postmenopausal women. The study indicated that women receiving MHT had a 69% lower likelihood of low BMD and higher T-scores at the lumbar spine and total hip compared to those not receiving it. This real-world evidence reinforces MHT's role in bone protection, despite historical concerns that have limited its uptake.

MedPage Today

Last reviewed Jun 17, 2026

Established / Validated

VerifiedMedical

Non-hormone medication addresses menopausal symptoms in women | Endocrine Society

A real-world study, OPTION-VMS, found that the FDA-approved non-hormone treatment fezolinetant significantly improved hot flashes, depression, and anxiety in women aged 40 to 75 experiencing menopausal vasomotor symptoms. The study's findings are consistent with those observed in clinical trials, providing reassurance about the medication's effectiveness in a broader population.

Endocrine Society

Professional Society

Last reviewed Jun 14, 2026

Established / Validated

VerifiedMedical

Management of menopause for women with cardiovascular disease

This document from the British Menopause Society provides detailed guidance on managing menopause in women with pre-existing cardiovascular conditions, including established ischemic heart disease, post-myocardial infarction, stroke, arrhythmias, congenital heart disease, spontaneous coronary artery dissection (SCAD), and valvular heart disease. It discusses the risks and benefits of menopausal hormone therapy (MHT/HRT) in these specific populations, often recommending individualized assessments and non-oral, low-dose estrogen with non-androgenic progestogens when HRT is considered.

thebms.org.uk

Last reviewed May 16, 2024

Showing 9 of 48 validated items.

View Full Evidence Library →

Editorial Series — The Interpretive Layer

The archive answers what is happening. The series help answer what it means.

Where the Evidence Radar surfaces and validates new findings, the Editorial Series sit alongside it as the interpretive layer—translating the evidence into the questions, decisions, and lived realities of the transition.

All Series →

Editorial Series

Biological Transitions with Relational Consequence

"This is not a relationship problem. It is a biological transition that the relational system was never designed to absorb without interpretation."

Read Series →

Editorial Series

Why Communication Advice Often Fails

"This is not a communication problem. It is a relational system operating beyond its functional capacity."

Read Series →

Editorial Series

The Hidden Relational Load

"This is not simply emotional overwhelm. It is the accumulation of invisible relational labor that is no longer being absorbed by the system."

Read Series →

Editorial Series

Relational System Stress

"This is not a relationship breakdown. It is a stable system under sustained stress losing its ability to regulate itself."

Read Series →

Editorial Series

Midlife Transition and Identity

"This is not a phase to fix or optimize. It is a reorganization of identity that changes how a person experiences themselves and their relationships."

Read Series →

Intelligence Toolset

Validated Evidence & Health Literacy

Validate Source Credibility

Enter the URL of any menopause-related news or medical article. Our radar will audit it for scientific citations, editorial standards, and marketing bias.

MenopauseDigest Brief

Receive Evidence-Based Menopause Insights—Without the Noise

Subscribe to the MenopauseDigest Brief (free)

Periodic summaries of new menopause research and reporting, evaluated for credibility and explained in real-world context.

No products. No promotions. No advice—just clarity.

Local-first privacyZero commercial biasUnsubscribe anytime
No sponsored content
No behavioral tracking
Search history, reflections, and translations remain on your device—not our servers

Submit question for consideration

Questions submitted here may inform future coverage or evidence-grounded Q&A. We cannot respond individually and do not provide medical advice.

0 / 700
Restoring Agency Through Inquiry